Defence Therapeutics Inc. (FRA:DTC)

Market Cap	19.58M -4.9%
Revenue (ttm)	n/a
Net Income	-2.21M
EPS	-0.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	5,194
Open	0.3500
Previous Close	0.3990
Day's Range	0.3500 - 0.4200
52-Week Range	0.3170 - 1.1700
Beta	n/a
RSI	46.10
Earnings Date	Feb 23, 2026

About Defence Therapeutics

Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; the anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; the ARM-X ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Country: Canada
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: DTC

Financial Performance

Financial numbers in CAD